HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

cifenline (cibenzoline)

Also Known As:

cibenzoline; 2-(2,2-diphenylcyclopropyl)-2-imidazoline; Bristol-Myers Squibb brand of cifenline succinate; Cipralan; Exacor; Pharmacia brand of cifenline succinate; cibenzoline succinate; cifenline succinate; cifenline, (S)-isomer

Networked: 164 relevant articles (29 outcomes, 30 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Azoles: 413
    - Imidazoles: 107
      - cifenline: 164

Experts

1.	Hamada, Mareomi: 7 articles (07/2014 - 01/2003)
2.	Shigematsu, Yuji: 6 articles (07/2014 - 01/2003)
3.	Komatsu, Takashi: 5 articles (09/2010 - 02/2002)
4.	Ogimoto, Akiyoshi: 4 articles (02/2011 - 01/2003)
5.	Ohtsuka, Tomoaki: 4 articles (05/2010 - 01/2003)
6.	Ikeda, Shuntaro: 3 articles (07/2014 - 08/2005)
7.	Saito, Makoto: 3 articles (02/2011 - 01/2003)
8.	Higaki, Jitsuo: 3 articles (02/2011 - 08/2005)
9.	Inaba, Shinji: 3 articles (02/2011 - 08/2005)
10.	Nakamura, Motoyuki: 3 articles (09/2010 - 06/2006)

Related Diseases

1.	Atrial Fibrillation 10/01/1985 - "We conclude that at 6 months cibenzoline is more effective than QAGS in preventing recurrent atrial fibrillation." 02/01/2002 - "[Relationship between long-term preventive efficacy of cibenzoline and atrial natriuretic peptide in patients with paroxysmal atrial fibrillation]." 02/01/2001 - "The efficacy of cibenzoline was assessed in the termination and long-term prevention of paroxysmal atrial fibrillation in relation to the time of onset in a series of patients with paroxysmal atrial fibrillation. " 02/01/2001 - "[Efficacy of cibenzoline in the termination and long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset]." 08/01/1990 - "Eight patients with frequent episodes of paroxysmal atrial fibrillation received oral cibenzoline (320 mg/day) for control of paroxysmal atrial fibrillation irrespective of the efficacy of intravenous cibenzoline. "
2.	Ventricular Tachycardia 10/01/1984 - "The efficacy of cibenzoline in preventing PES induction of ventricular tachycardia in the dog." 02/01/2002 - "He had taken 300 mg/day of cibenzoline for his sustained ventricular tachycardia (VT) for years. " 05/15/1998 - "Safety and tolerability of intravenous cibenzoline for acute termination of spontaneous sustained ventricular tachycardia. " 07/01/1992 - "Thus, the use of oral cibenzoline in patients with sustained spontaneous and inducible ventricular tachycardias showed a low antiarrhythmic efficacy at programmed stimulation and a high incidence of spontaneous ventricular tachycardia." 07/01/1992 - "However, spontaneous sustained ventricular tachycardia developed in three patients after initiation of cibenzoline treatment. "
3.	Cardiac Arrhythmias (Arrythmia) 03/01/1994 - "This efficacy, combined with the good tolerance of the treatment, makes it possible to recommend the prescription of cibenzoline as a first-line treatment for the prevention of atrial arrhythmia. " 02/01/1997 - "In conclusion, the efficacy of cibenzoline and flecainlde in the secondary prevention of atrial arrhythmia was found to be comparable, with 58% and 58% of patients in sinus rhythm, respectively, with a follow-up of 6 months." 03/01/1985 - "The pharmacokinetics of oral cibenzoline were studied in 30 arrhythmia patients as part of an ascending multiple-dose efficacy study. " 02/01/2000 - "Arrhythmia was reduced in 53% of the cases, after treating with betablocker or cibenzoline (4 cases). " 05/01/1995 - "In view of these results, cibenzoline may be administered first to prevent atrial arrhythmia."
4.	Tachycardia (Tachyarrhythmias) 09/01/1994 - "These results suggest that cibenzoline is effective for the treatment of postoperative supraventricular tachyarrhythmias in patients without impairment of ventricular function." 08/01/1990 - "In conclusion, cibenzoline might be effective in the treatment of atrial tachyarrhythmias. " 09/01/1994 - "The efficacy and safety of a single infusion of cibenzoline, a class I antiarrhythmic drug, were assessed in 86 patients presenting with a supraventricular tachyarrhythmia following heart surgery in a placebo-controlled double-blind parallel study. " 05/01/1993 - "A clinical study of intravenous cibenzoline in selected patients with recent-onset atrial tachyarrhythmia." 09/01/2006 - "We discovered that this was due to a documented intoxication with cibenzoline, an antiarrhythmic drug, used to treat (supra-)ventricular tachyarrhythmia. "
5.	Ventricular Premature Complexes (Premature Ventricular Contraction) 09/01/1987 - "Fifteen patients with ventricular premature complexes (VPCs) were included in this open study designed to assess the relative efficacy of bid (two times daily) and tid (three times daily) dosing regimens for cibenzoline as compared with qid (four times daily) administration. " 06/01/2000 - "Medication with cibenzoline (300 mg/day) for one month reduced the LVOT gradient at rest to 53 mmHg and strikingly improved symptoms and exercise tolerance and also suppressed premature ventricular contractions during exercise and alcohol consumption. " 07/01/1989 - "Cifenline in the short-term treatment of patients with ventricular premature complexes: a double-blind placebo-controlled study." 07/01/1992 - "Twenty-four hours of ambulatory monitoring during cibenzoline treatment (n = 9) showed no significant increase in the frequency of ventricular premature complexes. " 05/01/1986 - "The plasma concentration and antiarrhythmic effect data following multiple, ascending oral doses of cibenzoline in four patients with frequent premature ventricular contractions (PVCs) were analyzed using pharmacokinetic and pharmacodynamic modeling. "

Related Drugs and Biologics

1.	Flecainide (Tambocor)
2.	pilsicainide
3.	Disopyramide (Norpace)
4.	Quinidine (Chinidin)
5.	cifenline (cibenzoline)
6.	Procainamide (Procan)
7.	Propafenone (Rythmol)
8.	Anti-Arrhythmia Agents
9.	Polyvinyl Chloride (PVC)
10.	Atrial Natriuretic Factor (ANF)

Related Therapies and Procedures

1.	Electric Countershock (Cardioversion)
2.	Hemoperfusion
3.	Oral Administration
4.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
5.	Renal Dialysis (Hemodialysis)